Download PDF
Dtsch Med Wochenschr 2006; 131(34/35): 1873-1877
DOI: 10.1055/s-2006-949173
Übersicht | Review article
Gastroenterologie
© Georg Thieme Verlag KG Stuttgart · New York

HIV-HBV-Koinfektion - Diagnostik und Therapie

Clinical diagnostics and therapy of HIV-HBV-coinfected patientsS. Koch1 , K. Göbels1 , M. Oette1 , T. Heintges1 , A. Erhardt1 , D. Häussinger1
  • 1Klinik für Gastroenterologie, Hepatologie und Infektiologie, Universitätsklinikum Düsseldorf
Further Information

Publication History

eingereicht: 17.3.2006

akzeptiert: 3.8.2006

Publication Date:
17 August 2006 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Durch die stetige Abnahme der Mortalität und Morbidität der HIV-Infektion fokussieren sich heute die Probleme nicht mehr allein auf AIDS-spezifische Erkrankungen, sondern auch auf andere Ursachen wie virale Koinfektionen. Aufgrund sich überlagernder Transmissionswege von HIV und Hepatitis B sieht man Koinfektionen hier häufig. Patienten, die eine HIV-HBV-Koinfektion aufweisen, zeigen insgesamt einen ungünstigeren Verlauf der Hepatitis B-Infektion als Monoinfizierte. Komplexe immunologische Veränderungen unter einer HIV-Infektion führen zudem oftmals zu einem eher atypischen Verlauf der Hepatitis-B Infektion.

Wenn eine Therapieindikation der Hepatitis B vorliegt, sollte die Therapieindikation für die HIV-Infektion geprüft werden. Liegt hierfür keine Indikation vor, sollten HIV-wirksame Medikamente nicht eingesetzt werden, um Resistenzbildungen seitens des HI-Virus zu vermeiden. Besteht eine Indikation zur Behandlung beider Infektionen sollte eine antivirale Kombinationstherapie mit HBV-wirksamen Substanzen eingeleitet werden.

Summary

Owing to the steady decrease in mortality and morbidity of HIV-infection, current problems have not solely focussed on HIV-specific diseases, but also on other causes such as coinfections. Due to overlapping modes of transmission between HIV and HBV such coinfections have been frequently observed. Patients suffering from coinfections display overall a more unfavourable outcome compared to monoinfected patients. Complex immunologic changes during a HIV-infection often lead to an atypical course of HBV-infection.

Given the indication for treatment of HBV, the treatment indication for HIV should be considered. If such an indication has not been ruled out, HIV-directed medications should not be admistered in order to avoid the formation of resistant HIV strains. If an indication for treatment of both viruses has been demonstrated, an antiviral combination therapy should be initiated.

Schlüsselwörter

HIV-Infektion - Hepatitis B - HAART

Key words

HIV-infection - hepatitis B - HAART

Literatur

  • 1 Alberti A, Clumeck N, Collins S. et al . Short statement of the first european consensus conference on the treatment of chronic hepatitis B and C in HIV co-infected patients.  J Hepatol. 2005;  42 615-624
    Google Scholar
  • 2 Angus P, Vaughan R, Xiong S. et al . Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase.  Gastroenterology. 2003;  125 292-297
    Google Scholar
  • 3 Bang L, Scott L. Emtricitabine.  Drugs. 2003;  63 2413-2424
    Google Scholar
  • 4 Baraclude T M. (entecavir) package insert. Princeton (NJ): Bristol Meyers Squibb Company; Stand: März. 2005
    Google Scholar
  • 5 Benhamou Y, Thibault V, Vig P. et al . Safety and efficacy of adefovir dipivoxil in patients infected with lamivudine-resistant hepatitis B and HIV-1.  J Hepatol. 2006;  44 62-67
    Google Scholar
  • 6 Benhamou Y. Treatment algorithm for chronic hepatitis B in HIV-infected patients.  J Hepatol. 2006;  44 90-94
    Google Scholar
  • 7 Brook M, Gilson R, Wilkins E. British HIV Asssociation. BHIVA guidelines: coinfection with HIV and chronic hepatitis B virus.  HIV Med. 2003;  4 42-51
    Google Scholar
  • 8 Colin J F, Cazals-Hatem B, Loriot M A. et al . Influence of HIV infection on chronic hepatitis B in homosexual men.  Hepatology. 1999;  29 1306-1310
    Google Scholar
  • 9 Colonno R J, Rose R, Levine S M. et al . Emergence of entecavir resistant hepatitis B virus after one year of therapy in phase II & III studies is only observed in lamivudine refractory patients.  Hepatology. 2004;  40 661A
    Google Scholar
  • 10 Craxi A, Antonucci G, Camma C. Treatment options in HBV.  J Hepatol. 2006;  44 77-83
    Google Scholar
  • 11 Dusheiko G. Candidates for therapy: HBV.  J Hepatol. 2006;  44 84-89
    Google Scholar
  • 12 Erhardt A, Blondin D, Hauck K. et al . Response to interferon alfa is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than genotype D.  Gut. 2005;  54 1009-1013
    Google Scholar
  • 13 Häussinger D, Erhardt A, Oette M. Koinfektionen bei Hepatitis.  Z Gastroenterol. 2004;  42 724-730
    Google Scholar
  • 14 Hodge R. Telbivudine/ torcitabine Idenix/ Novartis.  Curr Opin Investig Drugs. 2004;  5 232-241
    Google Scholar
  • 15 Hofer M, Joller-Jemelka H I, Grob P J, Luthy R, Opravil M. Frequent chronic hepatitis B virus infection in HIV-infected patients positive for antibody to hepatitis B core antigen only. Swiss HIV Cohort Study.  Eur J Clin Microbiol Infect Dis. 1998;  17 6-13
    Google Scholar
  • 16 Hoff J, Bani-Sadr F, Gassin M, Raffi F. Evaluation of chronic HBV infection in coinfected patients receiving lamivudine as a component of anti-HIV regimens.  Clin Infect Dis. 2001;  32 963-969
    Google Scholar
  • 17 Huang A. Entecavir in HIV-HBV Co-Infection : Week 48 results (ETV-038). Abstract H-415. Abstracts of the 45th Interscience conference on antimicrobial agents and chemotherapy. Washington,DC 2005
    Google Scholar
  • 18 Hung C, Hsiao C. Isolated antibody to hepatitis B core antigen in individuals infected with HIV-1.  Clin Infect Dis. 2003;  37 1275-1276
    Google Scholar
  • 19 Lacombe K, Massari V, Girard P M. et al . Major role of hepatitis genotypes in liver fibrosis during coinfection with HIV.  AIDS. 2006;  20 419-427
    Google Scholar
  • 20 Marcellin P, Lau G K, Bonino F. et al . Peginterferon alfa -2a alone, lamivudine alone, and the two in combination in patients with HbeAg-negative chronic hepatitis B.  N Engl J Med. 2004;  351 1206-1217
    Google Scholar
  • 21 Marcellin P, Mommeja-Marin H, Sacks S. et al . A phase II dose-escalating trial of clevudine in patients with chronic hepatitis B.  Hepatology. 2004;  40 140-148
    Google Scholar
  • 22 Niederau C. Criteria for the treatment of chronic hepatitis b and d.  Z Gastroenterologie. 2004;  42 682-686
    Google Scholar
  • 23 Nunez M, Puoti M, Camino N, Soriano V. Treatment of chronic hepatitis B in the HIV-infected patients: present and future.  Clin Infect Dis. 2003;  37 1678-1685
    Google Scholar
  • 24 Perez-Olmeda M, Nunez M, Garcia-Samaniego J, Rios P, Gonzalez-Lahoz J, Soriano V. Distribution of hepatitis b virus genotypes in HIV-infected patients with chronic hepatitis B: therapeutic implications.  AIDS Res Human Retroviruses. 2003;  19 657-659
    Google Scholar
  • 25 Puoti M, Airoldi M, Bruno R. et al . Hepatitis B virus co-infection in human immundeficiency virus-infected patient: epidemiology, natural history and treatment.  Semin Liver Dis. 2003;  23 125-136
    Google Scholar
  • 26 Rehermann B. Immune responses in hepatitis B virus infection.  Semin Liver Dis. 2003;  23 21-37
    Google Scholar
  • 27 Schildgen O, Schewe C, Vogel M. et al . Successful therapy of hepatitis B with tenofovir in HIV infected patients failing previous adefovir and lamivudine treatment.  AIDS. 2004;  18 2325-2327
    Google Scholar
  • 28 Schildgen O, Sirma H, Funk A. et al . Variant of hepatitis B virus with primary resistance to adefovir.  N Engl J Med. 2006;  355 322-323
    Google Scholar
  • 29 Scotto G, Palumbo E, Fazio V, Tartaglia A, Saracino A, Angarano G. Clinical and virological response to adefovir dipovixil for lamivudine-resistant HBeAg-negative hepatitis B.  New Microbiol. 2005;  28 193-197
    Google Scholar
  • 30 Sheldon J A, Corral A, Rodes B. et al . Risk of selecting K65R in antiretroviral-naive HIV-infected individuals with chronic hepatitis B treated with adefovir.  AIDS. 2005;  19 2036-2038
    Google Scholar
  • 31 Soriano V, Puoti M, Bonacini M. et al . Care of patients with chronic hepatitis B and HIV coinfection: recommendations from an HIV-HBV International Panel.  Aids. 2005;  19 221-240
    Google Scholar
  • 32 Tassopoulos N C, Volpes R, Pastore G. et al., Lamivudine Precore Mutant Study Group . Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B.  hepatology. 1999;  29 889-896
    Google Scholar
  • 33 Tenney D J, Levine S M, Rose R E. et al . Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to lamivudine.  Antimicrob Agents Chemother. 2004;  48 3498-3507
    Google Scholar
  • 34 Thio C L, Seaberg E C, Skolasky R. et al . Multicenter AIDS Cohort Study: HIV-1, hepatitis B virus and risk of liver-related mortality in the Multicenter Cohort Study (MACS).  Lancet. 2002;  360 1921-1926
    Google Scholar
  • 35 Yoo B C, Kim J H, Lee K S. et al . A 24-week clevudine monotherapy produced profound on-treatment viral suppression as well as sustained viral suppression and normalisation of aminotransferase levels for 24 weeks off-treatment in HBeAg(+) chronic hepatitis B patients.  Hepatology. 2005;  42 270
    Google Scholar
  • 36 Zoulim F. Assesment of treatment efficacy in HBV infection and disease.  J Hepatol. 2006;  44 95-99
    Google Scholar

Dr. med. Stefanie Koch

Klinik für Gastroenterologie, Hepatologie und Infektiologie, Universitätsklinikum Düsseldorf

Moorenstraße 5

40225 Düsseldorf

Phone: +49/211/8116151

Fax: +49/211/8116294

Email: stefanie.koch@med.uni-duesseldorf.de

      >